TESS Foundation invests in Neurolentech’s approach for SLC13A5 - Neurolentech website

Skip to content

Neurolentech website

Precision Medicine for Neurodevelopmental Disorders

ABOUT
PIPELINE
NEWS
TEAM
CAREER
CONTACT

News Press release

TESS Foundation invests in Neurolentech’s approach for SLC13A5

Precision medicine for neurodevelopmental disorders.

Registered in Austria with company number 547172F

Registered in the UK with company number FC040474

ADDRESS

Neurolentech GMBH, Xista Science Park, Plöcking 1, 3400 Klosterneuburg, Austria

CONTACT INFO

Contact us

Registered in Austria with company number 547172F

Registered in the UK with company number FC040474

Copyright © Neurolentech - Alle Rechte vorbehalten.

Privacy policy